Valneva's Stock Soars 6.53% Midday After Stifel's Target Upgrade

On Tuesday, January 6th, at midday, Valneva's stock recorded a 6.53% increase to 4.0140 euros, following Stifel's recommendation which raised its price target from 9.50 euros to 10 euros while reiterating its buy recommendation. The stock had closed the previous day at 3.77 euros, marking a weekly gain of 7.1% that reflects a renewed investor interest. Trading volumes remain moderate with 0.6% of the capital traded during the session, but the magnitude of the bullish movement is significant in the context of this traditionally quiet early year period. On an annual basis, the performance remains spectacular with a 78.56% increase, driven by advances in the Franco-Austrian laboratory's clinical programs. Technically, the RSI at 47 now moves in a neutral zone after having approached overselling at the end of December, suggesting potential for continued rebound. The price progresses above its 50-day moving average established at 3.82 euros, confirming a positive short-term dynamic, and remains solidly above the 200-day moving average positioned at 3.48 euros, validating the underlying bullish trend. The MACD indicator shows a line at -0.03 and a signal line at -0.05, with a positive histogram at 0.02, indicating a gradual improvement in technical momentum. The support identified at 3.49 euros has been tested several times in recent weeks and appears to hold firmly, while the major resistance is at 4.30 euros, a level reached at the end of November which will be a key threshold to validate a sustainable recovery.

The American investment bank is particularly optimistic ahead of the Phase 3 results for VLA15, a vaccine developed in partnership with Pfizer against Lyme disease, expected in the first half of 2026, estimating that an efficacy of 70 to 80% would be perceived as a positive result. Stifel sees about 200% upside potential for the stock from its current levels in case of study success, and considers this catalyst to present a compelling risk-reward ratio. VLA15 is currently the only Lyme disease vaccine candidate in advanced clinical development, a bacterial disease transmitted by ticks affecting about 476,000 people annually in the United States and 130,000 in Europe. Given the significant unmet needs and the increasing prevalence of Lyme disease, Stifel estimates that the vaccine's maximum annual sales could reach 1.9 billion euros. If the results are positive, Valneva is expected to file a marketing authorization application in the second half of 2026, with potential approval in 2027 and a commercial launch targeted for the end of 2027. The analyst assigns an 80% probability of success to this Phase 3 study, based on the encouraging Phase 2 data published at the end of November which had demonstrated a strong immune response six months after the third booster dose. This outlook explains the enthusiasm of investors who anticipate a major catalyst likely to unlock significant valuation for the laboratory.

The Franco-Austrian laboratory reported a revenue of 127 million euros for the first nine months of 2025, up 8.9% compared to the same period of the previous year. However, this growth comes in a context marked by the FDA's suspension in November of the license for IXCHIQ, its chikungunya vaccine intended for travelers. On December 31, 2025, Valneva announced the termination of its licensing agreement with the Serum Institute of India regarding this vaccine, with the strategic goal of taking direct control of the supply chain and marketing in endemic countries where the disease risk is high. The adjusted EBITDA remains negative at -37.7 million euros over nine months, reflecting sustained investments in research and development estimated between 80 and 90 million euros for the year. Valneva has a cash reserve of 143 million euros at the end of the third quarter of 2025, which according to Stifel provides a sufficient financing horizon until the planned launch of VLA15 in 2027. To enhance operational efficiency, the group announced at the end of November the closure of its historic site in Nantes-Saint-Herblain and the transfer of all its French activities to Lyon, where the new headquarters will be established, while research and development will be centralized in Vienna, Austria. The one-month volatility stands at 8.82%, significantly lower than in previous weeks, characteristic of a gradual stabilization before the crucial results expected in the first half of 2026 for the Lyme disease vaccine.